Introduction In US biotech and pharma patent practice, the most important prior art reference is often not a patent at all. It is a paper in a peer-reviewed journal, a clinical trial registration, a conference abstract, or a regulatory submission....
Introduction US patent teams in 2026 are fighting on two fronts simultaneously. In prosecution, Section 101 Alice rejections continue to be the most common final rejection for software and AI patent applications — affecting more than 40% of applications in...
Introduction India is the world’s third-largest pharmaceutical patent filer. Its technology sector — centred in Bangalore, Hyderabad, and Pune — is generating an accelerating volume of software, semiconductor, and AI patent applications. Its regulatory environment for patent prosecution has undergone...
A granted patent is a starting point, not a finish line. The most defensible IP positions are built from patent families — parent patents extended through continuations and continuation-in-part applications that follow technology development and block competitive workarounds. Most companies...
Introduction Not every invention needs a patent. And not every invention that does not need a patent should be left unprotected. Defensive publication is the third option that most IP teams underuse — the deliberate disclosure of an invention to...
Introduction 85% of US patent applications receive at least one office action. For the average IP practice, office action response is not an occasional task — it is a constant workflow that determines prosecution outcomes, shapes claim scope, and drives...